IVOS Medical Announces BOSS G4™ Video Laryngoscope Sheath Designed to Improve Intubation Safety in High-Risk Patients

“Our BOSS G4 is designed to empower healthcare providers and first responders, and to raise the standard of care in intubation by improving outcomes in emergency intubation situations,” said Gabriel Punsalan, CRNA, MS, CEO and Co-Founder of IVOS Medical, Inc.

IVOS Medical, Inc., a startup medical device company specializing in airway management, today announced the development of its BOSS G4™,  an economical, single-use video laryngoscope sheath designed to enhance intubation safety, particularly for high-risk patients in emergency or soiled intubations. The BOSS G4 is compatible with existing video laryngoscope platforms and incorporates novel features to help maintain clear vision and provide continual oxygen delivery during intubation. IVOS Medical is initiating commercialization for the BOSS G4 and continuing product refinements, targeting market entry in 2026. See video here.

“Our BOSS G4 is designed to empower healthcare providers and first responders, and to raise the standard of care in intubation by improving outcomes in emergency intubation situations,” said Gabriel Punsalan, CRNA, MS, CEO and Co-Founder of IVOS Medical, Inc.

About the IVOS BOSS G4™

The integrated IVOS BOSS (Breathing Optimization and Suction System) enables continuous suction by accommodating various suction methods, effectively clearing aspirate and debris from the esophagus and trachea. Additionally, the sheath offers independent oxygen delivery, ensuring a clear tracheal view for precise tube placement and improved first-pass success rates. By minimizing the time patients go without oxygen, it improves both the safety and success rates of critical interventions—particularly vital in emergency, perioperative, and intensive care settings, where achieving first-pass intubation success is paramount.

 

Share:

Other News

Neogap Therapeutics Selected for EIC Soft-landing Programme in Boston

The EIC Soft-landing Programme provides business development support and opportunities to connect with investors, academic institutions and life science stakeholders in Boston – a global hub for cancer research and biotechnology. Neogap’s combination of AI, bioinformatics and cell biology in developing personalised immunotherapy aligns well with the programme’s focus on deep tech companies.